Advertisement

Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 770–771 | Cite as

ASO Author Reflections: Long-Term Survival Is Feasible After Complete CRS/HIPEC for Biphasic Peritoneal Mesothelioma

  • Konstantinos Chouliaras
  • Konstantinos I. VotanopoulosEmail author
ASO Author Reflections
  • 45 Downloads

Notes

Disclosures

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237–42.CrossRefGoogle Scholar
  2. 2.
    Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686–93.CrossRefGoogle Scholar
  3. 3.
    Votanopoulos KI, Sugarbaker P, Deraco M, et al. Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Ann Surg Oncol. 2018;25(3):667–73.CrossRefGoogle Scholar
  4. 4.
    Mazzocchi AR, Rajan SAP, Votanopoulos KI, Hall AR, Skardal A. In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening. Sci Rep. 2018;8(1):2886.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Konstantinos Chouliaras
    • 1
  • Konstantinos I. Votanopoulos
    • 1
    Email author
  1. 1.Division of Surgical Oncology, Department of General SurgeryWake Forest Baptist HealthWinston-SalemUSA

Personalised recommendations